INS and type 1 diabetes mellitus: The TOP1 Trial was designed based on the OPTIMIZE study conducted by Mathieu et al. in Belgium and Canada, to assess the effect of treatment optimization with OD Gla-300 in combination with a prandial rapid-acting insulin in patients with T1D with HbA1c between 8 and 10% on BID basal insulin as part of basal-bolus therapy [23].